ArticleAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2026
Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Hypertrophic Cardiomyopathy: A Retrospective Cohort Study.
Article in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal anticoagulation strategy for patients with atrial fibrillation (AF) and obstructive hypertrophic cardiomyopathy (oHCM) remains unclear. This study compared the outcomes of direct oral anticoagulants (DOACs) versus warfarin in this patient population.
methodsData from the TriNetX Research Network were used to identify patients with AF and oHCM treated with either DOACs or warfarin. Patients with a prior history of stroke were excluded. Propensity score matching (PSM) was performed to balance baseline characteristics. The primary outcome was ischemic stroke. Secondary outcomes included: all-cause death, all-cause hospitalization, acute myocardial infarction, gastrointestinal bleed, hematuria, and brain hemorrhage. Hazard ratios (HRs) were estimated by Cox proportional hazard models.
resultsA total of 7090 patients in the DOAC group and 3350 in the warfarin group were included prior to PSM. Following PSM, each cohort included 3307 patients. The incidence of ischemic stroke was lower in the DOAC group (3.5%) compared with the warfarin group (4.8%), with a hazard ratio (HR) of 0.74 (95% confidence interval [CI]: 0.58-0.95). All-cause mortality was similar between groups, with 555 (16.8%) deaths in the DOAC group and 575 (17.4%) in the warfarin group (HR: 0.996, 95% CI: 0.89-1.12). All-cause hospitalization rates were lower in the DOAC group (64.5%) compared with the warfarin group (68.7%) (HR: 0.90, 95% CI: 0.85-0.95). No significant differences were observed in the rates of acute myocardial infarction (12.1% versus 12.2%; HR: 1.01, 95% CI: 0.88-1.16), gastrointestinal bleeding (6.9% versus 7.9%; HR: 0.89, 95% CI: 0.74-1.06), hematuria (8.0% versus 8.5%; HR: 0.96, 95% CI: 0.82-1.14), or intracranial hemorrhage (1.5% versus 2.0%; HR: 0.75, 95% CI: 0.52-1.09) between groups.
conclusionsDOACs demonstrated a lower risk of ischemic stroke and all-cause hospitalization rates compared with warfarin in patients with AF and oHCM, supporting the use of DOACs in this patient population.
Indexed as
Identifiers
41838376What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.